ESMO 2022 | KEYNOTE-B10: pembro + carbo + pacli as 1L therapy in recurrent/metastatic HNSCC

Marcin Dzienis, MD, Gold Coast University Hospital, Southport, Australia, provides an overview of the Phase IV KEYNOTE-B10 (NCT04489888) trial, which evaluated the safety and efficacy of pembrolizumab combined with carboplatin and paclitaxel as first-line treatment of patients with recurrent or metastatic head and neck squamous carcinoma. The primary outcome was objective response rate (ORR) and secondary outcomes included duration of response (DoR), progression-free survival (PFS) and overall-survival (OS). The combination demonstrated a 42% response rate, which confirmed this combination had antitumor activity with a manageable safety profile. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.